Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in advanced biliary tract cancer
NCT06591520Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of ivonescimab in biliary tract cancer (BTC) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Overall Survival at 2 years. Started Oct 2024; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06591520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06591520.